- Home
- NRXS vs MCRB Comparison
NRXS vs MCRB Comparison
Compare NRXS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | MCRB |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 71.0M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NRXS | MCRB |
|---|---|---|
| Price | $7.01 | $7.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $13.00 | ★ $14.00 |
| AVG Volume (30 Days) | 90.2K | ★ 115.3K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,569,282.00 | $789,000.00 |
| Revenue This Year | $172.91 | N/A |
| Revenue Next Year | $115.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.20 | $5.31 |
| 52 Week High | $9.33 | $29.98 |
Technical Indicators
Market Signals| Indicator | NRXS | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 58.51 |
| Support Level | $6.79 | $6.56 |
| Resistance Level | $7.79 | $8.29 |
| Average True Range (ATR) | 0.36 | 0.65 |
| MACD | 0.05 | 0.22 |
| Stochastic Oscillator | 62.50 | 86.36 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.